Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Shimura, Takaya ^a   Yoshida, Michihiro ^a   Fukuda, Shinji ^b   Ebi, Masahide ^a   Hirata, Yoshikazu ^a   Mizoshita, Tsutomu ^a   Tanida, Satoshi ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Higashiyama, Shigeki ^b,c   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY   (Japan)

Author keywords

Cancer invasion; EGFR; Gastric cancer; HB EGF

Indexed keywords

HEPARIN BINDING EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CELL MOTILITY; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN DOMAIN; PROTEIN LOCALIZATION; STOMACH CANCER; WILD TYPE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; STOMACH NEOPLASMS; WOUND HEALING;

EID: 84861568000     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-205     Document Type: Article

References (30)

1. International Agency for Research on Cancer GLOBOCAN 2008 http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (last accessed on December 16, 2011), International Agency for Research on Cancer GLOBOCAN 2008.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
3. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 2008, 99:214-220. 10.1111/j.1349-7006.2007.00676.x, 18271917.
4. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21. 10.1677/erc.0.0100001, 12653668.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232. 10.1016/1040-8428(94)00144-I, 7612182.
6. Kinugasa Y, Hieda M, Hori M, Higashiyama S. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 2007, 282:14797-14806. 10.1074/jbc.M611036200, 17392284.
7. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003, 163:489-502. 10.1083/jcb.200303017, 2173632, 14597771.
8. Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, et al. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer 2009, 100:1320-1329. 10.1038/sj.bjc.6605010, 2676553, 19337254.
9. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, Tanida S, Joh T. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res 2008, 14:3956-3965. 10.1158/1078-0432.CCR-07-4794, 18559618.
10. Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, Shudou M, Taguchi T, Hieda Y, Higashiyama S. Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 2008, 180:763-769. 10.1083/jcb.200710022, 2373455, 18299347.
11. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, Hanakawa Y, Ohmoto H, Yoshino K, Shirakata Y, et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol 2000, 151:209-220. 10.1083/jcb.151.2.209, 2192647, 11038170.
12. Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P, Abraham J, Klagsbrun M. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993, 90:3889-3893. 10.1073/pnas.90.9.3889, 46411, 8483908.
13. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
14. Nanba D, Inoue H, Shigemi Y, Shirakata Y, Hashimoto K, Higashiyama S. An intermediary role of proHB-EGF shedding in growth factor-induced c-Myc gene expression. J Cell Physiol 2008, 214:465-473. 10.1002/jcp.21233, 17674363.
15. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003, 100:3221-3226. 10.1073/pnas.0537588100, 152273, 12621152.
16. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007, 26:2006-2016. 10.1038/sj.onc.1209999, 17001310.
17. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, Fang L, Lee SW. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004, 64:5283-5290. 10.1158/0008-5472.CAN-04-0925, 15289334.
18. Inui Y, Higashiyama S, Kawata S, Tamura S, Miyagawa J, Taniguchi N, Matsuzawa Y. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994, 107:1799-1804.
19. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994, 202:1705-1709. 10.1006/bbrc.1994.2131, 8060360.
20. Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K, Mizuno H, Ishiguro S, Kiyohara T, Miyazaki Y, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002, 98:505-513. 10.1002/ijc.10198, 11920609.
21. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996, 66:315-321. 10.1002/(SICI)1097-0215(19960503)66:3<315::AID-IJC8>3.0.CO;2-1, 8621250.
22. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, Pfeiffer DG, Schildberg FW, Pfeiffer A. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003, 162:115-132. 10.1007/978-3-642-59349-9_10, 12790326.
23. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005, 92:1737-1745. 10.1038/sj.bjc.6602536, 2362036, 15827558.
24. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Shterev DI, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S. The EGFR ligands Amphiregulin and Heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res 2011, 17:3619-3630. 10.1158/1078-0432.CCR-10-2475, 21482691.
25. Wang F, Sloss C, Zhang X, Lee SW, Cusack JC. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 2007, 67:8486-8493. 10.1158/0008-5472.CAN-07-0498, 17875687.
26. Singh AB, Tsukada T, Zent R, Harris RC. Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cells. J Cell Sci 2004, 117:1365-1379. 10.1242/jcs.01037, 14996914.
27. Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007, 109:2016-2024. 10.1002/cncr.22627, 17394193.
28. Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH, Rajjayabun PH, Mellon JK, Freeman MR. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res 2003, 63:484-490.
29. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 2009, John Wiley & Sons, Inc, Hoboken NJ, 7.
30. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M, Mekada E, Taniguchi N. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995, 6:967-980. 301256, 7579712.